STOCK TITAN
  1. Home
  2. News
  3. IOBT

IO Biotech, Inc. - IOBT STOCK NEWS

Welcome to our dedicated page for IO Biotech news (Ticker: IOBT), a resource for investors and traders seeking the latest updates and insights on IO Biotech stock.

IO Biotech, Inc. (IOBT) is a clinical-stage biopharmaceutical company dedicated to developing innovative immune therapies for treating cancer. Their focus is on creating first-in-class immune-modulating anti-cancer treatments based on a groundbreaking platform technology. This platform enables the activation of T cells that specifically target immune inhibitory molecules.

IO Biotech has a robust pipeline featuring two leading immune-modulating therapies, IDO and PD-L1, which are currently in clinical development. Additionally, several other compounds are nearing the end of the preclinical phase. The company's proven track record in advancing compounds to the clinical stage underscores their expertise and commitment to innovation in cancer treatment.

The company's product candidates utilize the T-win technology platform, designed to trigger the immune system to attack and disrupt multiple pathways that regulate tumor-induced immunosuppression. This unique approach aims to enhance the body's natural ability to fight cancer, offering a promising avenue for patients battling this disease.

With an experienced management team and a world-class advisory board, IO Biotech is well-positioned in the field of immuno-oncology. Recent achievements include the advancement of their pivotal Phase 3 Clinical Trial (IOB-013/KN-D18) and significant progress with their drugs IO102 and IO103. The company’s dedication to cutting-edge research and development is evident through their continuous efforts in preclinical and clinical trials.

For the latest updates and detailed information about IO Biotech, their therapies, ongoing projects, and financial condition, visit their official website or contact Maryann Cimino, Director of Investor Relations, at mci@iobiotech.com.

News

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Rhea-AI Summary
IO Biotech presents new data at AACR Annual Meeting 2024 supporting the use of a dual antigen approach to enhance anti-tumor activity, showcasing the potential of IO102-IO103 in creating an environment for increased anti-tumor effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
none
-
News

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Rhea-AI Summary
IO Biotech appoints Faiçal Miyara, Ph.D., as Chief Business Officer to drive global business development activities and strategic partnerships. Dr. Miyara brings over 17 years of experience in the pharmaceutical industry and will focus on advancing the T-Win platform. The company anticipates key milestones in 2024 and 2025, including the Phase 3 interim analysis of their lead therapeutic cancer vaccine, IO102-IO103, and the readout of the primary endpoint of progression-free survival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
management
-
News

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Rhea-AI Summary
IO Biotech (IOBT) presents new nonclinical data at AACR 2024 showcasing the individual contributions of IO102 and IO103 in controlling tumor growth. The abstract highlights the dual antigen vaccine's impact on immune suppression and T effector function, supporting its potential in benefiting patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
none
News

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Rhea-AI Summary
IO Biotech (IOBT) reported completing enrollment of the pivotal Phase 3 trial of its lead cancer vaccine, IO102-IO103, in combination with KEYTRUDA in patients with advanced melanoma. The company expects an interim analysis for overall response rate in Q3 2024. They also dosed the first patient in a Phase 2 trial of IO102-IO103 in combination with pembrolizumab for solid tumors. IO Biotech ended 2023 with $143.2 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
none
-
News

IO Biotech to Present at 44th Annual Cowen Health Care Conference

Rhea-AI Summary
IO Biotech (IOBT) to Present at 44th Annual Cowen Health Care Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
conferences
-
News

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) has announced the dosing of the first patient in its Phase 2 trial studying treatment with IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® in neoadjuvant and adjuvant patients with resectable melanoma or squamous cell carcinoma of the head and neck. The company is conducting a pivotal Phase 3 trial in patients with advanced melanoma, with enrollment completed and an interim analysis planned in 2024. IO Biotech aims to help patients in earlier disease settings with its neoadjuvant/adjuvant trial, IOB-032, involving leading global experts from centers of excellence in the US, Australia, and Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
clinical trial
News

IO Biotech Announces 2023 Third Quarter Results

Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) reports completion of enrollment in pivotal Phase 3 trial of IO102-IO103 cancer vaccine in combination with KEYTRUDA®. Encouraging preliminary data from Phase 2 basket trial presented at major medical conferences. Company ended Q3 with $165.5 million in cash, expects to support operations into Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
earnings
-
News

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) appoints industry veteran Dr. Helen Collins, MD, to its board of directors, signaling potential advancements in cancer vaccine development. Dr. Collins brings extensive drug development and corporate strategy experience and will serve on the Research and Development Committee. IO Biotech aims to potentially bring its lead cancer vaccine candidate, IO102-IO103, to market for advanced melanoma patients as early as 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
management
-
News

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) completes enrollment in pivotal Phase 3 trial for IO102-IO103 in combination with KEYTRUDA® in patients with advanced melanoma. Phase 1/2 data showed promising results, with 80% of patients achieving a response and 50% achieving a complete response. The trial is expected to reach the primary endpoint of progression-free survival in the second half of 2025, with an interim analysis in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
clinical trial
News

IO Biotech Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) announces participation in Jefferies London Healthcare Conference and Piper Sandler 35th Healthcare Conference. CEO Mai-Britt Zocca and CFO Amy Sullivan to attend one-on-one meetings in London. Fireside chat with CEO Mai-Britt Zocca at Piper Sandler conference in New York. Webcast link provided for the event. Webcast replay available on company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences

FAQ

What is the current stock price of IO Biotech (IOBT)?

The current stock price of IO Biotech (IOBT) is $1.2 as of November 1, 2024.

What is the market cap of IO Biotech (IOBT)?

The market cap of IO Biotech (IOBT) is approximately 79.1M.

What does IO Biotech, Inc. do?

IO Biotech, Inc. develops innovative immune therapies for the treatment of cancer, focusing on immune-modulating anti-cancer therapies.

What are IO Biotech's leading therapies?

Their leading therapies target IDO and PD-L1, both currently in clinical development.

What technology platform does IO Biotech use?

They use the T-win technology platform, which aims to induce the immune system to disrupt multiple pathways regulating tumor-induced immunosuppression.

What is the company's track record in advancing therapies?

IO Biotech has a proven track record of progressing compounds to the clinical stage.

Who is part of IO Biotech's team?

They have an experienced management team in immuno-oncology and a world-class advisory board.

What recent achievements has IO Biotech made?

Recent achievements include the advancement of pivotal Phase 3 Clinical Trials and progress with drugs IO102 and IO103.

How can I get the latest updates on IO Biotech?

You can visit their official website or contact their Director of Investor Relations, Maryann Cimino, at mci@iobiotech.com.

What is the focus of IO Biotech's research?

Their research focuses on developing first-in-class immune-modulating cancer vaccines.

What is unique about IO Biotech's approach to cancer treatment?

Their unique approach involves activating T cells to specifically target immune inhibitory molecules, enhancing the body's ability to fight cancer.

How can I contact IO Biotech for more information?

You can contact Maryann Cimino, Director of Investor Relations, at 617-710-7305 or via email at mci@iobiotech.com.

Stock IOBT logo
IO Biotech, Inc.

Nasdaq:IOBT

IOBT Rankings

#4547 Ranked by Market Cap
N/A Ranked by Dividends

IOBT Stock Data

79.06M
65.88M
0.24%
76.66%
0.42%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
COPENHAGEN